FBRX - Forte Biosciences, Inc.
28.76
-1.520 -5.285%
Share volume: 256,968
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$30.28
-1.52
-0.05%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-14-2024 | 11-14-2024 | 03-28-2025 | 05-15-2025 | 08-14-2025 | 11-14-2025 | |
| Assets | ||||||||
| Total Assets | 32.017 M | 26.078 M | 17.946 M | 61.561 M | 47.459 M | 107.783 M | 97.089 M | |
| Current Assets | 31.502 M | 25.711 M | 17.668 M | 61.346 M | 47.158 M | 107.616 M | 95.412 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 36.121 M | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 30.444 M | 24.498 M | 16.363 M | 22.244 M | 45.856 M | 106.144 M | 93.414 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 106.000 K | 96.000 K | 86.000 K | 77.000 K | 125.000 K | 110.000 K | 148.000 K | |
| Other Assets | 409.000 K | 271.000 K | 192.000 K | 138.000 K | 176.000 K | 57.000 K | 1.529 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 32.017 M | 26.078 M | 17.946 M | 61.561 M | 47.459 M | 107.783 M | 97.089 M | |
| Total liabilities | 3.332 M | 9.117 M | 8.580 M | 9.081 M | 9.032 M | 9.170 M | 12.992 M | |
| Total current liabilities | 3.332 M | 9.117 M | 8.580 M | 9.081 M | 9.032 M | 9.170 M | 12.992 M | |
| Accounts Payable | 1.685 M | 5.275 M | 5.159 M | 4.879 M | 5.023 M | 5.301 M | 5.491 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 28.685 M | 16.961 M | 9.366 M | 52.480 M | 38.427 M | 98.613 M | 84.097 M | |
| Common stock | 154.627 M | 155.419 M | 156.208 M | 206.467 M | 208.081 M | 279.516 M | 282.688 M | |
| Retained earnings | -125.940 M | -138.451 M | -146.843 M | -153.998 M | -169.654 M | -180.903 M | -198.585 M |